Prosecution Insights
Prosecution Insights
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (25%) |
| §112 only | 1 (25%) |
| No statute on record | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIFLE, BRUCK | 1 | 79.2% | +15.9% |
| LANKFORD JR, LEON B | 1 | 69.8% | +31.0% |
| SCHMITT, MICHAEL J | 1 | 56.6% | +21.7% |
| STEELE, AMBER D | 1 | 59.1% | +9.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18269837 | NRF2-ACTIVATING COMPOUND | KIFLE, BRUCK | 14d |
| 17831843 | THERAPEUTIC DRUG FOR DISEASES RELATED TO ENDOPLASMIC RETICULUM CELL DEATH IN CORNEAL ENDOTHELIUM | SCHMITT, MICHAEL J | 33d |
| 18330510 | CORNEAL ENDOTHELIUM ECM THERAPEUTIC MEDICAMENTS | LANKFORD JR, LEON B | 54d |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1657 | 1 |
| 1629 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18269837 | NRF2-ACTIVATING COMPOUND | KIFLE, BRUCK | 1624 | §112 | Final Rejection | 14d | Pending | Jun 27, 2023 |
| 18330510 | CORNEAL ENDOTHELIUM ECM THERAPEUTIC MEDICAMENTS | LANKFORD JR, LEON B | 1657 | §102 | Final Rejection | 54d | Pending | Jun 07, 2023 |
| 17831843 | THERAPEUTIC DRUG FOR DISEASES RELATED TO ENDOPLASMIC RETICULUM CELL DEATH IN CORNEAL ENDOTHELIUM | SCHMITT, MICHAEL J | 1629 | Other | Final Rejection | 33d | Pending | Jun 03, 2022 |
| 17610844 | COMPOSITION FOR PREVENTING OR TREATING NEUROTROPHIC KERATITIS WHICH CONTAINS PACAP PEPTIDE OR STABILIZED PACAP PEPTIDE | STEELE, AMBER D | 1658 | Other | Non-Final OA | 22d | Pending | Nov 12, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial